Ibi3031
Phase 1
Innovent Biologics (Suzhou) Co. Ltd.Ibi3031 is one of 20 therapeutic programs targeting Thyroid Eye Disease. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
19
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
23 competitors in Thyroid Eye Disease
#DrugCompanyPhaseTrials
1Medrol
PfizerApproved
Zolymbus
AbbVieApproved
Timolol Maleate
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
TEPEZZA
HHorizon Therapeutics Ireland DAC
Approved
AMG 333
AmgenPhase 2
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 1
IBI311
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
VRDN-003
VViridian Therapeutics, Inc.
Phase 3
Batoclimab
IImmunovant Sciences GmbH
Phase 3
Khn939
BBeijing Kanghong Biological Medicine Co., Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Ibi3031. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]